The US FDA Approves Jaguar Health’s Clinical Trial Protocol for Canalevia-CA1 to Treat Chemotherapy-Induced Diarrhea in Dogs
Shots:
- The US FDA has agreed to the clinical trial design and conduct proposed by Jaguar Health for the evaluation of Canalevia-CA1 (crofelemer delayed-release tablets) for the treatment of CT-induced diarrhea (CID) in dogs. The company expects to receive the US FDA’s full approval based on this trial
- Earlier in Dec 2021, Jaguar received the US FDA’s conditional approval for Canalevia-CA1 to treat CID in dogs. Later in Dec 2023, the conditional approval was renewed to a validity up until 21st Dec 2024
- Canalevia-CA1 is an oral plant-based (canine-specific formulation of crofelemer) prescription product conditionally approved by the US FDA, received through the MUMS pathway
Ref: Jaguar Health | Image: Jaguar Health
Related News:- Jaguar Health’s Canalevia-CA1 Receives Conditional Approval Renewal from the US FDA for Chemotherapy-Induced Diarrhea in Dogs
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
